Review Article
CODEN (USA): IJPLCP

ISSN: 0976-7126
Turan & Kaur, 11(9):6983-6988, 2020

International Journal of Pharmacy & Life Sciences
Open Access to Researcher

Prospective Study of Pharmacovigilance in India -A Review

SachinTuran*and Prabhleen Kaur

Department of Pharmacology, C T Institute of pharmaceutical Sciences, Jalandhar (Punjab)-India

Article info

Received: 10/08/2020

Revised: 09/09/2020

Accepted: 30/09/2020

www.ijplsjournal.com

Abstract

Pharmacovigilance (PV) is the pharmacological science relating to the collection, detection, assessment, monitoring and prevention of adverse effects with pharmaceutical products. The serious issue in India is the under-revealing of adverse drug reaction (ADR). There is an expanding number of hospitalization of patients attributable to unfriendly impacts of medications and it turns into a test to discover the specific reason of the ADRs when a patient in rewarded with various medications all the while. In the audit, we will investigate the various sorts of evaluation scale to do the ADR appraisal and to locate its causative operators.

Key words: Pharmacovigilance, Adverse drug reaction, Hospitalization, Medication

Introduction

According to World Health Organization (WHO), Pharmacovigilance (PV) is defined as the pharmacological science and activities relating to the monitoring, detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) [1-4]. ADR is considered to be the sixth driving explanation for death in India, with a current population of 1.35 billion, is that the fourth biggest makers of doctor prescribed medications inside the world with very 6000 authorized producers and more than 60000 marked formulations inside the market. In the United States of America, ADRs contribute 3-7% of emergency clinic confirmations. In England, 1% accounts of the whole clinic affirmations were expected to ADRs during the time 1999-2008. ADRs square measure normal in Australian human services framework moreover and that they add to a 1% of medical clinic admissions [5-6]. The PV exertion inside the India is facilitated by the Indian Pharmacopoeia Commission (IPC) and directed by the Central Drugs Standard Control Organization (CDSCO). The most duty of the IPC is to keep up and build up the PV database comprising of all presumed genuine ADR to prescriptions watched is working as a National Coordination Centre (NCC) for Pharmacovigilance Program of India (PvPI). NCC is working underneath the heading of council that suggests strategies and rules for regulatory interventions [7]. The fundamental obligation of NCC is to observe all the ADR of medicine being seen inside the Indian populace and to create and keep up its own PV data. The point of the commission that demonstrations simply like the NCC for PvPI is for wellbeing of the patient, security of the populace with pertinence utilization of the medication. Pharmacovigilance is a significant and indistinguishable part of clinical research. Both clinical trials safety and post-marketing pharmacovigilance (Popularly known as Post- marketing studies or Phase IV clinical trials) are critical throughout the product life cycle.

***Corresponding Author**
E.mai: sachinturan90@gmail.com

With a sensibly high number of recent high-profile drug withdrawals, both the pharmaceutical industry as well as different regulatory authorities over the globe have increased current standards. Early recognition of signs from the post-marketing reconnaissance examines and clinical trials in early stages have now been adjusted by significant pharmaceutical organizations so as to recognize the dangers related with their therapeutic items as ahead of schedule as could be expected under the circumstances. In the event that any such hazard is available, at that point successfully dealing with the dangers by applying robust risk management plans throughout the life cycle of product is adopted. These hazards the executive's plans are additionally generally known as Risk Minimisation Programs/Strategies. Thalidomide which is reintroduced for Multiple reason like Myeloma and Lepra responses through S.T.E.P.S. program (System for Thalidomide Education and Prescribing Safety) is a classic example. Signal recognition and risk management/minimisation has added another measurement to the field of pharmacovigilance and has driven it to be an advancing control; which requires continuous refinement so as to build its pertinence and incentive to general wellbeing [8,9].

History of Pharmacovigilance Programmed in India

The commencement of pharmacovigilance in India goes back to 1986, when a lineal adverse drug reaction (ADR) observance system consisting of 12 regional centres, each covering a population of 50 million, was planned for India.

India connected with the World Health Organization's (WHO) Adverse Drug Reaction (ADR) Monitoring Programmed based in Uppsala, Sweden in the year 1997. In India, for the observation of Adverse Drug Reaction (ADR's), there were three primary centers known**:**

1. A National Pharmacovigilance Centre in the Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi.
2. WHO special centers in Mumbai (KEM Hospital).
3. Jawahar Lal Nehru Hospital, Aligarh Muslim University, Aligarh**.**

These centers report ADRs to the drug regulatory authority of India CDSCO (Central drugs standard control organization). The significant job of these centers was to monitor ADRs to prescription drugs which are showcased in India. Be that as it may, they barely worked as data about the need to report ADRs and about the elements of these observing focuses were yet to arrive at the prescribers and there was absence of funding from the government. This attempt was failed and hence, again from the first of January 2005, the WHO-supported and World Bank-funded National Pharmacovigilance Program for India was made operational. The National Pharmacovigilance Program made in January 2005, was to be supervise by the National Pharmacovigilance Advisory Committee situated in the Central Drugs Standard Control Organization (CDSCO), New Delhi. Two zonal centers-the South-West zonal center (placed in the Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai) and the North-East zonal center (located in the Department of Pharmacology, AIIMS, New Delhi), were to collect information from all over the country and Transfer it to the Commission as well as to the Uppsala Monitoring center in Sweden. Three regional centers would report to the Mumbai center and two to the New Delhi center. Each regional center in turn would have many peripheral centers reporting to it. Currently there are 150 adverse drug reaction monitoring centers (AMC) across the country are functioning and reporting's ADR to National coordination center (NCC), Pharmacovigilanceprogrammed of India (PvPI) at Indian pharmacopoeia commission (IPC), Ghaziabad. The pharmacovigilance programmed of India (PvPI) was started by government of India on 14 JULY 2010 with the all institute of medical sciences (AIIMS), New Delhi as the National Coordination Center for monitoring Adverse drug reaction in the country for safe- guarding public health.[10]

Need of pharmacovigilance

Pharmacovigilance is actually post marketing surveillance. It is essential fornumberof reasons to monitor drugs after they are marketed. The factors of involvement can be broadly categorized into two [11]

(a)Human factors (b) Post marketing topics.

Among human factors that are of consideration are –

a) Insufficient evidence of safety from clinical trial, since they are of a short duration, often for only a few weeks.

b) Animal experiments, during clinical trials often do not simulate human Pharmacodynamics and Pharmacokinetics.

i) During clinical trials, the population size is limited-not more than 5000, and often as small as 500 volunteers.

ii) The population segment is narrow, and is age and sex specific.

iii) The trials give narrow indications since only the specific disease is studied.

Adverse drug reaction

An adverse drug reactions (ADRs) can be characterized as an unintended and harmful responses to a health product which causes at the doses usually used or tested for the diagnosis, prevention or treatment of a disease or the alteration of an organic function[12,13]Though, it is hard to acknowledge the causative agent related with the adverse drug reactions (ADRs) because the drug include more than one ingredients.[14]All drugs are capable of producing adverse drug reactions (ADRs) and whenever a drug is given a risk is taken.[15].The significance of risk has to be considered along with significance of expected therapeutic benefit in determining whether to use or not to use a particular drug in a given patient.The adverse drug reactions (ADRs) may create quickly or only after prolonged medication or even after stoppage of drug. Adverse drug reactions (ADRs) are not rare; an incidence of 10- 25% has been documented in different clinical settings and are more common with the multiple drug therapy [6, 4, 15]. Adverse drug reactions (ADRs) have been classified into two ways:

A. Predictable (Type-A) Reactions

These are based on pharmacological properties of drugs but quantitatively normal response to the drug which include side effects, toxic effects and consequences of drug withdrawal[6,13].

Example- Beta-blocker cause Bradycardia.

B. Unpredictable (Type-B) Reactions

These are based on individuality of patient and not on drug's known actions; include allergy and idiosyncrasy. They are less common, non dose dependent, generally more serious and require withdrawal of drug. [6, 13].

Example -Penicillin cause anaphylaxis & Anticonvulsant cause hypersensitivity.

Table 1: Known drug adverse effects

Drugs	Adverse Drug Reactions (ADRs)
Thalidomide	Phocomelia, Multiple defects
Methotrexate	Multiple defects, fetal death
Androgen	Virilization, limb, esophageal, cardiac defects
Progestins	Virilization of female fetus
Stilboestrol	Vaginal carcinoma in teenage female offspring
Tetracyclines	Discolored or deformed teeth, retarded bone growth
Warfarin	Nose, eye and hand defects, growth retardation
Phenytoin	Various malformations
Lithium	fetal goiter, cardiac and other abnormalities
Aspirin/Indomethacin	Premature closer of ductus arteriosus

Adverse Drug Reactions (ADRs) Reporting

Adverse Drug Reactions (ADRs) Reporting/ Adverse Event (AE) Reporting is the most commonly associated with Pharmacovigilance (PV) and take in significant amount of resources of government agencies or drug regulatory authorities or drug safety departments in pharmaceutical organizations [16]. Adverse Event (AE) reporting considers the receipt, triage, data maintaining, evaluation, distribution, reporting of AE data[17,18,19].The foundation of AE reports may include solicited reports from patient support programs, reports from clinical or post-marketing studies, spontaneous reports from healthcare professionals or patients or other intermediaries, reports from literature sources, reporting is a regulatory requirement in most countries, reports from the media including social media and websites and reports reported to drug regulatory authorities themselves [20]. For pharmaceutical companies AE reporting also provides data that play an important role in assessing the risk-benefit

profile of a given drug. The following are several elements of Adverse Event (AE) Reporting: [21,22]

1. An identifiable patient.
2. An identifiable reporter.
3. A suspect drug.
4. An adverse event.

Reporting of adverse drug reaction

Suspected ADR reporting forms for consumers is available on the website of IPC to report ADR. To get rid of barrier in ADR reporting, the consumer reporting form are available in 10 different languages (Hindi, Tamil, Telugu, Kannada, Bengali, Gujarati, Assamese, Marathi, Oriya, and Malayalam). ADRs will be reportable via PvPI helpline number (18001803024) on week days from 9:00 am to 5:30 pm. The mobile Android application for ADR reporting has conjointly been created available to the general public [22].


MEDICINES SIDE EFFECT REPORTING FORM (FOR CONSUMERS)

Indian Pharmacopoeia Commission, National Coordination Centre- Pharmacovigilance Programme of India, Ministry of Health & Family Welfare, Government of India.

1.Patient Details

Patient Initials: | Gender (√): Male Female Other | Age (Year or Month):

2. Health Information

a. Reason(s) for taking medicine(s)(Disease/Symptoms):

b. Medicines Advised by (√): Doctor Pharmacist Friends/Relatives Self (Past disease experienced/No past disease experienced)

3. Details of Person Reporting the Side Effect

Name (Optional):

Address:

Telephone No: | Email:

4. Details of Medicine Taking/Taken

Name of Medicines	Quantity of Medicines taken (e.g. 250 mg, Two times a day)	Expiry Date of Medicines	Date of Start of Medicines	Date of Stop of Medicines
			dd/mm/yy	
			dd/mm/yy	
			dd/mm/yy	

Dosage form (√) : Tablet Capsule Injection Oral Liquids If Others (Please Specify.....)

5. About the Side Effect

When did the side effect start? dd/mm/yy | Side Effect is still Continuing (Yes/No):

When did the side effect stop? dd/mm/yy

6.How bad was the Side Effect? (Please √ the boxes that Apply)

Did not affect daily activities | Affect daily activities

Admitted to hospital | Death

Others

7.Describe the Side Effect (What did you do to manage the side effect?)

This reporting is voluntary, has no legal implication and aims to improve patient safety. Your active participation is valuable. The information provided in this form will be forwarded to ADR Monitoring Centre for follow-up. You are requested to cooperate with the programme officials when they contact for more details. Please do report even if you do not have all the information.

Fig. 1: Suspected ADR reporting form for consumer

Conclusion

The adverse drug reaction observance and reporting programmed or pharmacovigilance programmed of India is aim to determine the risks related to the utilization of the drugs. PV remains a dynamic part of the clinicians and the general population. After the appearance of these adverse drugs effects, it is very essential that these are reported timely and analyzed. Not only the doctors should be aware of the PV programmed but the patients themselves should be made aware of this so self-reporting is increased and the burden on the clinicians is also reduced. India is still in the growingg phase of PV and more reporting is necessary to reach the world's standard of reporting these adverse events to provide effective drug use in children's and pregnant women which is one of the most vulnerable populations of all. The PV programmed must be able to identify these adverse events timely in the coming years with the help of clinicians, patients, and the pharmaceutical industry to help shape the safety of patients themselves. Therefore, currently this point has return to aware the general public too for the reporting the adverse drug reaction to nearest hospital or ADR monitoring center or to the health care professionals. They will directly report the adverse drug reaction through government. Toll-free number 18001803024, adverse drug reaction application, email and alternative methodology like social medias. India is now contemplating to be a hub for clinical research. The DCGI has shown its seriousness to ensure safety of drugs by set up the National Pharmacovigilance Program. More and more clinical trials are now being conducted in India and business process outsourcing (BPOs) based in India are now also undertaking pharmacovigilance projects from MNCs. Healthcare professionals, consumer groups, NGOs and hospitals should understand that there is now a system in place to collect and examine adverse event data. They should start reporting adverse events actively and participate in the National Pharmacovigilance Program to help ensure that people in India receive safe drugs. With the help of all stakeholders, let us pledge to make this happen in India and build a world-class pharmacovigilance system. We can surely make this happen if we work together.

References

1. Nimesh S. and Prem Parkash K.A.(2019). Targeted Pharmacovigilance Study on Antitubercular Drugs in the Department of Pulmonary Medicine at Tertiary Care Teaching Hospital in Rural Area,*International Journal of Pharmacovigilance*, 4.1:1-6.

2. Nimesh S and Ashwlayan V.D.(2018). Pharmacovigilance: An Overview,*International Journal of Pharmacovigilance*, 3.1: 1-6.
3. Central TB Division.(2006). Directorate general of health services, *ministry of health and family welfare.TB India. New Delhi, India: MFHW*.
4. Simon L., Wei m., Robin M., Vikraman G. and Stuart N. (2005). Astandardized drug nomenclature links systems that use different vocabularies, so the patient gets what the doctor ordered.05:17-23.
5. Srivastava S.K.(2017). A complete textbook of medical pharmacology. *1st edition, Chapter*, 56, 888.
6. Zhu Z. (2018). Selective upper airway stimulation in older patients,*Respiratory Medicine*,140: 77-81.
7. Protocol for National Pharmacovigilance Program.(2004). CDSCO, *Ministry of Health and Family Welfare, Government of India. November.*
8. Lazarou J., Pomeranz B. and Corey P. (1998) Incidence of adverse drug reactions in hospitalized patients: *A meta-analysis of prospective studies, JAMA*, 279:1200-5.
9. SkalliS.andSoulaymani B. R. (2012). Safety monitoring of herb-drug interations: acomponent of pharmacovigilance. *Drug Saf*, 35:785-791.
10. Sujatha S. (2017). Need for Pharmacovigilance, *Annals of Pharmacology and Pharmaceutics*, 2.2:1-2.
11. Bhosale U., Jaiswal S., Yegnanarayan R. and Godbole G. (2013). A Pharmacovigilance Study of AntiAsthmatic Agents in Patients of Bronchial Asthma at a Tertiary Care Hospital, *Journal of Clinical & Experimental Research, 1, May-August*: 26-30.
12. Sharma S., Phadnis P. and Gajbhiye S.(2013) Pharmacovigilance: Its Awareness and Impact Care Teaching Medical College in Central India Impact-Study in a Tertiary care Teaching Medical College in Central India", *International Journal of Pharmaceutical Research and BioScience,* 2: 234-247.
13. Maiti B., Nagori B.P., Singh R., Kumar P. and Upadhyay N. (2011). Recent Trends in Herbal Drugs: A Review, *International Journal of Drug Research and Technology*, 1: 17-25.
14. Kumar M. R., Bodhanapu S., Mani T.,Tamizh, Phaneendra P. and Rahiman O.M. (2011) Pharmacovigilance and its importance in drug regulation: An Overview, *Scholars Research Library*, 3:165-179.
15. Kulkarni M.D., Baig M.S., Chandaliya K.C., Doifode S.M., Razvi S.U. and Sidhu N.S. (2013). Knowledge, Attitude and Practice of Pharmacovigilance among Prescribers of Government Medical College and Hospital, Aurangabad (Maharashtra), *International journal of pharmacology and therapeutics*, 3: 10-18.
16. Shuka S.S., Gidwani B., Pandey R., Rao S.P., Singh V. and Vyas A. (2012). Importance of Pharmacovigilance in Indian Pharmaceutical Industry, *Asian Journal of Research in Pharmaceutical Science,* 2: 04-08.
17. Elkalmi R.M., Mohamed A. H., Mohamed I. M., Ibrahim W.T., EfanM.A. and Muhammad H.A. (2011). Pharmacy Students' Knowledge and Perceptions about Pharmacovigilance in Malaysian Public Universities", *American Journal of Pharmaceutical Education*,75.7:96.
18. Kothari M., Sadaria P. and Dave N. (2013). Data mining in pharmacovigilance – to reduce Adverse Drug Effects (ADRs), *International Journal of Computer Applications & Information Technology,* II, January: 01-04.
19. Reddy V., Lokesh, Pasha S.K., Javeed, Dr. Rathinavelu M. and Dr. Reddy Y.P. (2014). Assessment of Knowledge, Attitude and Perception of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting among the Pharmacy Students in South India", IOSR

Journal of Pharmacy and Biological Sciences, 9, Mar-Apr: 34-43.

20. Muraraiah S., Rajarathna K., Sreedhar D., Basavalingu D. and Jayanthi C.R. (2011). A questionnaire study to assess the knowledge, attitude and practice of Pharmacovigilance in a paediatric tertiary care centre, *Journal of Chemical and Pharmaceutical Research: 416-422.*

21. AmarnathS., JaikumarS., BasalingappaS., ThulasimaniM. and RamaswamyS. (2013). Pharmacovigilance for Health Care Professional Students, *Research Journal of Pharmaceutical, Biological and Chemical Sciences,* 4, January-March:1204-1217.

22. Biswas P. (2013). Pharmacovigilance in Asia, *Journal of Pharmacology and Pharmacotherapeutics,* December, 4: S7-S19.

Cite this article as:
Turan S. and Kaur P. (2020). Prospective Study of Pharmacovigilance in India -A Review, *Int. J. of Pharm. & Life Sci.*, 11(9): 6983-6988.
Source of Support: Nil
Conflict of Interest: Not declared
For reprints contact: ijplsjournal@gmail.com